HIV pulmonary complications: Difference between revisions
No edit summary |
(Strip excess bold) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Most common cause of pneumonia in HIV | *Pulmonary disease is the most common reason for hospitalization in HIV/AIDS patients | ||
*Most common cause of pneumonia in HIV: [[Strep pneumo|''Streptococcus pneumoniae'']] (not [[PCP]]) | |||
*Risk of opportunistic infections increases as CD4 count declines: | |||
**CD4 >200: Bacterial pneumonia, [[tuberculosis]] | |||
**CD4 <200: [[PCP|Pneumocystis jirovecii pneumonia (PCP)]] | |||
**CD4 <100: Fungal infections (histoplasmosis, coccidioidomycosis), [[Mycobacterium avium complex]] | |||
**CD4 <50: CMV pneumonitis | |||
==Clinical Features== | ==Clinical Features== | ||
*Varies by organism: | |||
**Bacterial: Acute onset, productive cough, fever, focal consolidation | |||
**PCP: Subacute (weeks), dry cough, progressive dyspnea on exertion, [[hypoxia]] out of proportion to exam, bilateral diffuse infiltrates | |||
**TB: Chronic cough, night sweats, weight loss; may have upper lobe cavitary disease or atypical patterns with low CD4 | |||
**Kaposi sarcoma (pulmonary): Dyspnea, hemoptysis; skin/mucosal lesions often present | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
| Line 8: | Line 19: | ||
==Evaluation== | ==Evaluation== | ||
*[[ | *[[CXR]] — essential first step: | ||
* | **Lobar consolidation → bacterial | ||
*[[ | **Bilateral diffuse interstitial/ground-glass → PCP | ||
*[[ | **Upper lobe cavitary disease → TB | ||
**Nodules, pleural effusions → fungal, TB, lymphoma, [[Kaposi sarcoma]] | |||
*[[ABG]]/SpO2 — resting and with exertion (PCP may show desaturation only with ambulation) | |||
*Labs: CBC, LDH (elevated in PCP), CD4 count, [[blood cultures]], sputum (Gram stain, culture, AFB) | |||
*Induced sputum for PCP (silver stain or DFA) | |||
*CT chest if CXR non-diagnostic | |||
*Cannot use [[PORT score]] to disposition HIV patients (not validated in this population) | |||
==Management== | ==Management== | ||
*Treat based on suspected organism; see individual disease pages for antibiotic templates | |||
*Always isolate until TB ruled out (negative AFB × 3 or clinical exclusion) | |||
*Start empiric antibiotics for bacterial pneumonia per standard CAP guidelines while workup pending | |||
*Low threshold for ICU admission — HIV patients decompensate rapidly | |||
==Disposition== | ==Disposition== | ||
* | *Low threshold for admission; most HIV patients with pneumonia require inpatient treatment | ||
*ICU for respiratory failure, severe hypoxia, hemodynamic instability | |||
==See Also== | ==See Also== | ||
*[[HIV - AIDS (Main)]] | |||
*[[PCP]] | |||
*[[Tuberculosis]] | |||
*[[Community acquired pneumonia]] | |||
*[[Neutropenic fever]] | |||
==References== | ==References== | ||
Latest revision as of 09:28, 22 March 2026
Background
- Pulmonary disease is the most common reason for hospitalization in HIV/AIDS patients
- Most common cause of pneumonia in HIV: Streptococcus pneumoniae (not PCP)
- Risk of opportunistic infections increases as CD4 count declines:
- CD4 >200: Bacterial pneumonia, tuberculosis
- CD4 <200: Pneumocystis jirovecii pneumonia (PCP)
- CD4 <100: Fungal infections (histoplasmosis, coccidioidomycosis), Mycobacterium avium complex
- CD4 <50: CMV pneumonitis
Clinical Features
- Varies by organism:
- Bacterial: Acute onset, productive cough, fever, focal consolidation
- PCP: Subacute (weeks), dry cough, progressive dyspnea on exertion, hypoxia out of proportion to exam, bilateral diffuse infiltrates
- TB: Chronic cough, night sweats, weight loss; may have upper lobe cavitary disease or atypical patterns with low CD4
- Kaposi sarcoma (pulmonary): Dyspnea, hemoptysis; skin/mucosal lesions often present
Differential Diagnosis
HIV associated conditions
- HIV neurologic complications
- HIV pulmonary complications
- Ophthalmologic complications
- Other
- HAART medication side effects[1]
- HAART-induced lactic acidosis
- Neuropyschiatric effects
- Hepatic toxicity
- Renal toxicity
- Steven-Johnson's
- Cytopenias
- GI symptoms
- Endocrine abnormalities
Evaluation
- CXR — essential first step:
- Lobar consolidation → bacterial
- Bilateral diffuse interstitial/ground-glass → PCP
- Upper lobe cavitary disease → TB
- Nodules, pleural effusions → fungal, TB, lymphoma, Kaposi sarcoma
- ABG/SpO2 — resting and with exertion (PCP may show desaturation only with ambulation)
- Labs: CBC, LDH (elevated in PCP), CD4 count, blood cultures, sputum (Gram stain, culture, AFB)
- Induced sputum for PCP (silver stain or DFA)
- CT chest if CXR non-diagnostic
- Cannot use PORT score to disposition HIV patients (not validated in this population)
Management
- Treat based on suspected organism; see individual disease pages for antibiotic templates
- Always isolate until TB ruled out (negative AFB × 3 or clinical exclusion)
- Start empiric antibiotics for bacterial pneumonia per standard CAP guidelines while workup pending
- Low threshold for ICU admission — HIV patients decompensate rapidly
Disposition
- Low threshold for admission; most HIV patients with pneumonia require inpatient treatment
- ICU for respiratory failure, severe hypoxia, hemodynamic instability
See Also
References
- ↑ Gutteridge, David L MD, MPH, Egan, Daniel J. MD. The HIV-Infected Adult Patient in The Emergency Department: The Changing Landscape of the Disease. Emergency Medicine Practice: An Evidence-Based Approach to Emergency Medicine. Vol 18, Num 2. Feb 2016.